The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 5.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 8%. The street (34 analysts) rates it buy, with a mean price target of $6252.
Britannia Industries
BRITANNIA.NS · NSE · INR · Market cap $1.24T
Britannia Industries Limited manufactures and sells various food products in India and internationally.
PASS · Titan Ethical · score 70.0Price as of 13 Nov 2026Daily close, not a live quoteLast reviewed 4 days ago
Screened 2026-11-13 · the tape above runs as of 12:01 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price4,783.00 INR at the 13 Nov 2026 close
- Our value readFair vs our fair value, as of 13 Nov 2026
- Our regime readMarkup, as of 16 Nov 2026
- Ethical screenPasses, score 70.0 out of 100
- Last reviewed13 Nov 2026 (4 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: 4,320.00 INR to 5,063.32 INR, base estimate 4,402.89 INR (screen dated 2026-11-13).
- Trend Markup
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options no verdict drawn today, left as found
- Ethical passes the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its markup label.
Britannia Industries holds its Markup at $4,783.00. Consolidating, no directional conviction, held for 7 days.
| Phase | Markup |
| Quantitative state | Consolidating, no directional conviction, held for 7 days |
| Price at the screen | $4,783.00 |
| Valuation | 47.43 trailing · 38.50 forward price to earnings |
| Values screen | PASS · score 70.0 |
| Beta | 0.47 |
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 14.36% | Below 33% | Interest-bearing debt is just 14.4% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 0.12% | Below 33% | Cash held in interest-bearing accounts and securities is 0.1% of assets, under the one-third limit. | Pass |
| Receivables | 7.08% | Below 49% | Money owed to the company is 7.1% of assets, under the 49% limit. | Pass |
| Revenue purity | 0.86% | Below 5% | Only 0.9% of revenue comes from non-compliant sources, under the 5% line. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Clears, in Plain English
Britannia Industries clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 14%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-11-16. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when BRITANNIA.NS's ethical verdict changes
Today BRITANNIA.NS passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads Fair vs our fair value, as of 13 Nov 2026: it trades above our 4,402.89 INR fair value estimate, 7.90% revenue growth.
How a fair value is estimated: discounted cash flow (DCF).
Fair value range in INR, drawn from the 2026-11-13 screen. The gold marker is the market price at the same screen. The price runs 8.6% above the base estimate.
Third-party analyst targets: 34 covering, consensus Buy. The average target sits +30% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & ProjectionsWhere our models see it going: fair-value estimate 4,402.89 INR, with a range of 4,320.00 INR to 5,063.32 INR, dated to the 2026-11-13 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsWhy it is worth knowing
A quality business. At the screened price it sits 9% above our 4,402.89 INR fair value: priced for the quality, not a bargain.
| Forward P/E | 38.5xexpensive even after accounting for its growth |
| Trailing P/E | 47.4xexpensive: the price assumes strong growth ahead |
| EPS, trailing | 105.38 |
| EPS, forward | 129.81 |
| Revenue growth | +7.9%slow but positive growth |
| Profit margin | 13.2%thin but positive margins |
| Return on equity | 53.3%an exceptional return on shareholder capital |
| Dividend yield | 1.70% |
| Debt to equity | 0.27minimal debt: a conservative balance sheet |
| Beta | 0.47barely tracks the market's swings |
| 52-week range | 5,035.00 - 6,336.00 |
| Market cap | $1.24T |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: its business and earnings are exposed to India and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeBRITANNIA.NS trades on NSE (the company is based in India). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 4.1% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Our forward projection puts the odds of a 10% gain over the next month near 8%. The street (34 analysts) rates it buy, with a mean price target of $6252.
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 0.5% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 8%. The street (34 analysts) rates it buy, with a mean price target of $6252.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 3.5% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading oversold. Our forward projection puts the odds of a 10% gain over the next month near 8%. The street (34 analysts) rates it buy, with a mean price target of $6252.
The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 3.2% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading oversold. Our forward projection puts the odds of a 10% gain over the next month near 8%. The street (34 analysts) rates it buy, with a mean price target of $6252.
The framework has shifted from accumulation to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading oversold. Our forward projection puts the odds of a 10% gain over the next month near 8%. The street (34 analysts) rates it buy, with a mean price target of $6252.
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading oversold. Our forward projection puts the odds of a 10% gain over the next month near 8%. The street (34 analysts) rates it buy, with a mean price target of $6252. It reported earnings in this window, a natural checkpoint for the thesis.
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading oversold. Our forward projection puts the odds of a 10% gain over the next month near 8%. The street (34 analysts) rates it buy, with a mean price target of $6252. It reported earnings in this window, a natural checkpoint for the thesis.
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading oversold. Our forward projection puts the odds of a 10% gain over the next month near 8%. The street (34 analysts) rates it buy, with a mean price target of $6252. It reported earnings in this window, a natural checkpoint for the thesis.
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading oversold. Our forward projection puts the odds of a 10% gain over the next month near 8%. The street (34 analysts) rates it buy, with a mean price target of $6252. It reported earnings in this window, a natural checkpoint for the thesis.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
This entry now belongs to the ledger. Whatever BRITANNIA.NS does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.